PBA
ACLX

Paradigm Biocapital Advisors’s Arcellx ACLX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$663M Buy
5,774,016
+50,000
+0.9% +$4.41M 13.55% 1
2025
Q4 		$373M Buy
5,724,016
+1,075,000
+23% +$85.8M 9.53% 3
2025
Q3 		$382M Hold
4,649,016
– – 10.86% 3
2025
Q2 		$306M Buy
4,649,016
+156,984
+3% +$9.77M 13.07% 2
2025
Q1 		$295M Buy
4,492,032
+120,431
+3% +$8.16M 13.5% 2
2024
Q4 		$335M Buy
4,371,601
+371,601
+9% +$32.1M 11.66% 2
2024
Q3 		$334M Buy
4,000,000
+151,905
+4% +$10.1M 11.3% 2
2024
Q2 		$212M Buy
3,848,095
+30,000
+0.8% +$1.63M 8.13% 3
2024
Q1 		$266M Buy
3,818,095
+159,471
+4% +$10.1M 9.35% 2
2023
Q4 		$203M Buy
3,658,624
+705,502
+24% +$31.8M 9.51% 2
2023
Q3 		$106M Buy
2,953,122
+606,122
+26% +$20.9M 7.19% 3
2023
Q2 		$74.2M Buy
2,347,000
+589,221
+34% +$22.5M 5.73% 4
2023
Q1 		$54.2M Buy
1,757,779
+875,678
+99% +$26.6M 5.13% 7
2022
Q4 		$27.3M Buy
+882,101
New +$20.2M 3.21% 16

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Paradigm Biocapital Advisors's ACLX Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Arcellx (ACLX) stake by 0.87% in Q1 2026, buying an estimated $4.41M and bringing the position to 5,774,016 shares worth $663M. The position accounts for 13.55% of the portfolio, ranked #1.

Paradigm Biocapital Advisors first reported a position in ACLX in Q4 2022 and has held it in 14 quarters since. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • Paradigm Biocapital Advisors held 5,774,016 shares of Arcellx worth $663M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 50,000 Arcellx shares in Q1 2026, an estimated $4.41M.
  • Arcellx made up 13.55% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #1 holding.
  • Paradigm Biocapital Advisors first reported a position in Arcellx in Q4 2022 and has held it in 14 quarters since.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.